Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals. It operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic candidate, TLX591, is a lutetium-labeled radio antibody-drug conjugate (rADC) in a Phase 3 trial for advanced prostate cancer. The company also develops TLX250 for advanced metastatic kidney cancer, TLX101 for glioblastoma, TLX66 for bone marrow conditioning in hematopoietic stem cell transplant, and Illuccix and Gozellix for prostate cancer. Additional pipeline candidates include TLX592, TLX252, TLX400, TLX102, TLX300, and TLX090, as well as BiPASS, AlFluor, TLX250-Px, and TLX101-Px. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally, and has a strategic collaboration with University Hospital Essen. Founded in 2015, it is headquartered in North Melbourne, Australia.